We are live on ! Find out more
LMAT icon

LeMaitre Vascular

80.89 USD
-2.60
3.11%
At close Updated Nov 6, 4:00 PM EST
Pre-market
After hours
80.89
0.00
0%
1 day
-3.11%
5 days
-1.43%
1 month
2.33%
3 months
0.09%
6 months
-26.61%
Year to date
0.9%
1 year
-5.5%
5 years
47.91%
10 years
269.53%
 

About: LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Employees: 655

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 38.5%
Neutral 53.8%
Negative 7.7%
Neutral
GlobeNewsWire
7 hours ago
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre to Participate in Upcoming Investor Conferences
Positive
MarketBeat
2 days ago
LeMaitre Vascular Q3 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast.
LeMaitre Vascular Q3 Earnings Call Highlights
Negative
Zacks Investment Research
2 days ago
LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.
LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates
Neutral
GlobeNewsWire
2 days ago
LeMaitre Q3 2026 Financial Results
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
LeMaitre Q3 2026 Financial Results
Neutral
Seeking Alpha
6 days ago
Dividend Income Report: +15.25% And A Listener's Portfolio Roast
This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. He holds 29 stocks with roughly equal weight, so I built a mock $100,000 portfolio and reviewed it the way I review my own money. The current portfolio yield is 1.78%, with a 5-year dividend growth CAGR of 11.69%.
Dividend Income Report: +15.25% And A Listener's Portfolio Roast
Neutral
GlobeNewsWire
25 days ago
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
Positive
Seeking Alpha
1 month ago
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
Neutral
PRNewsWire
1 month ago
LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed
National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.
LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed
Positive
Zacks Investment Research
2 months ago
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Neutral
GlobeNewsWire
2 months ago
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre to Participate at Upcoming Investor Conferences in September
Price charts implemented using Lightweight Charts™